Cynata Therapeutics (ASX: $CYP) announces positive initial data from CYP-006TK trial

Cynata Therapeutics Limited (ASX: $CYP) has released encouraging initial data from its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU). The trial showed a median percentage reduction in wound surface area of 87.6% in the active CYP-006TK group after 10 weeks, compared to 51.1% in the control group. Recruitment in the trial is progressing well, with 25 out of a planned 30 participants now enrolled.

Executive Commentary on CYP-006TK trial

These initial results are very promising, and consistent with the previous data readout. We look forward to completing enrolment in the near future, which will take us a step closer to our objective of demonstrating safety and efficacy of CYP-006TK in DFU.

Summary of CYP-006TK trial and outlook

Cynata Therapeutics (ASX: $CYP) has reported positive initial data from the Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers. The trial demonstrated a significant median percentage reduction in wound surface area in the active CYP-006TK group after 10 weeks, indicating potential efficacy in promoting wound healing in patients with DFU. With recruitment progressing well, the Company aims to enroll a total of 30 participants and continue the trial as planned. These results are in line with the Company's objective of demonstrating safety and efficacy of CYP-006TK in DFU, and the outlook appears promising for the advancement of this potential treatment option.